What is tesamorelin?
Tesamorelin is a lab-made version of growth hormone–releasing hormone (GHRH), the signal the brain sends to tell the pituitary gland to release growth hormone. Branded tesamorelin is approved for one narrow use, reducing excess belly fat in adults with HIV-associated lipodystrophy. Compounded tesamorelin is different from an FDA-approved product: it is not FDA-approved.
These articles cover how tesamorelin works, what its clinical trials measured, side effects, and how it compares with other growth-hormone peptides. It is prescription-only: a licensed provider reviews every request, and not everyone qualifies.
25 articles on this topic
-
Egrifta Prescribing Information, Explained
Egrifta WR’s label covers one HIV-related use, a daily dose, four contraindications, monitoring, side effects, and product-specific storage. WR and SV directions cannot be swapped.
-
Tesamorelin Fatty Liver Trial: What It Found
A 12-month trial found less liver fat and less worsening of scarring with tesamorelin. Its 61 participants had HIV, a virus that weakens the immune system, which limits what the findings mean for everyone else.
-
13 Questions to Ask Before Tesamorelin
A tesamorelin review turns on a short list: what you want it for, your cancer, pregnancy and pituitary history, and your blood sugar and IGF-1. Here are the questions worth bringing, and the label line or trial finding behind each.
-
Tesamorelin News Update: September 2026
A quiet quarter for the medicine itself: Egrifta's label and its narrow use did not change. The news came from around it, in FDA's letters to online sellers, WADA's 2027 list and three new papers.
-
Tesamorelin Clinical Trials: What the Studies Show
The large trials found less visceral abdominal fat in adults with HIV-associated lipodystrophy. They did not test general weight loss, anti-aging, or the compounded formulations sold today.
-
MOTS-c vs Tesamorelin: Not a Fat-Loss Contest
MOTS-c and tesamorelin work through different systems, and their evidence is not comparable. Tesamorelin has large late-stage trials for one narrow HIV-related condition; MOTS-c does not yet have completed human treatment results.
-
Tesamorelin vs Tirzepatide: Which Fits Which Goal?
Tesamorelin and tirzepatide can both change fat-related measures, but they answer different clinical questions. One has narrow evidence for deep abdominal fat in adults with HIV lipodystrophy; the other was studied for total body weight.
-
Does Tesamorelin Build Muscle? What Trials Show
Tesamorelin raised lean mass modestly in trials of adults with HIV-related lipodystrophy, but that is not proof of bigger or stronger muscles. It has not been shown to build muscle in healthy lifters.
-
Tesamorelin Before and After: The Study Timeline
Expect an early lab signal, not a one-month change in the mirror. The strongest trials measured deep abdominal fat at 26 and 52 weeks, all in adults with HIV-associated lipodystrophy.
-
Is Tesamorelin a Steroid? No—It's a GHRH Peptide
Tesamorelin is a peptide signal, not an anabolic steroid or growth hormone itself. It prompts the pituitary to release growth hormone, but sport rules still prohibit it.
-
Tesamorelin 10 mg: What the Vial Number Means
A tesamorelin 10 mg label describes the total peptide in the vial, not the amount in one injection. The prescribed amount, liquid volume, and days of supply come from the pharmacy label and provider's plan.
-
Tesamorelin Cost: Brand vs. Compounded Prices
Public brand benchmarks run from about $6,000 a month at wholesale list price to roughly $10,709 for a 28-day cash quote. Insurance may bring that down for HIV-associated lipodystrophy; compounded tesamorelin follows a separate cash-pay path.
-
Tesamorelin Cycle: Why Doctors Talk About Duration
There is no on-and-off tesamorelin cycle in the research. The trials ran it daily for 26 weeks and then 52 — and when people stopped, the visceral fat came back.
-
What Is Tesamorelin Used For?
Tesamorelin has one narrow labeled use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Uses beyond that label need a more careful answer.
-
Tesamorelin Half-Life Is Measured in Minutes
Tesamorelin leaves the bloodstream quickly, but the signal it starts can last much longer. That difference explains why trials used it once daily and why providers follow IGF-1 instead of watching the clock.
-
Tesamorelin for Women: Evidence and Menopause
Tesamorelin for women has limited female-specific evidence: pivotal trials enrolled 84%–86% men, and no trial was designed for menopause-related abdominal change. Hormone therapy, pregnancy, glucose and IGF-1 all change the prescribing conversation.
-
Tesamorelin Injections: Sites, Timing, and Storage
Tesamorelin is injected under the skin once daily. The abdomen, site rotation, timing, device format, and storage instructions all matter—and they are not identical across branded and compounded formulations.
-
Does Tesamorelin Work? What the Trials Show
Tesamorelin reduced visceral abdominal fat in two large phase 3 trials, but those studies involved adults with HIV-associated lipodystrophy. The evidence does not establish it as a general weight-loss medication or promise the same result for every patient.
-
Tesamorelin vs CJC-1295: Evidence and Differences
Both peptides signal through the GHRH receptor, but their structures, duration and human evidence differ sharply. The clearest distinction is phase 3 visceral-fat data for tesamorelin versus biomarker studies for CJC-1295.
-
Is Tesamorelin FDA Approved? Not Every Form
Egrifta has an indication-specific approval for adults with HIV and lipodystrophy. Tesamorelin offered here is dispensed as a compounded medication, which is different from an FDA-approved product: the formulation is not FDA-approved.
Page 1 of 2 · 25 articles